Oppenheimer & Co’s Achieve Life Sciences ACHV Stock Holding History

Oppenheimer & Co’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-21,300	Closed	-$104K	–	1363
2022 Q2	$104K	Sell	21,300 -1,000	-4%	-$6.78K	﹤0.01%	1333
2022 Q1	$169K	Sell	22,300 -2,500	-10%	-$18.6K	﹤0.01%	1379
2021 Q4	$193K	Sell	24,800 -200	-0.8%	-$1.57K	﹤0.01%	1402
2021 Q3	$213K	Buy	25,000 +2,000	+9%	+$15.7K	﹤0.01%	1369
2021 Q2	$207K	Buy	+23,000	New	+$219K	﹤0.01%	1408
2015 Q3	–	Sell	-7	Closed	-$35K	–	1346
2015 Q2	$35K	Buy	+7	New	+$34.7K	﹤0.01%	1450

Other funds holding ACHV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Oppenheimer & Co's ACHV Position: Q3 2022 in Review

Oppenheimer & Co sold out of Achieve Life Sciences (ACHV) in Q3 2022, closing a stake of 21,300 shares — an estimated $104K sold.

Oppenheimer & Co first reported a position in ACHV in Q2 2015 and held it in 6 quarters. The position peaked at $213K in Q3 2021. 28 funds tracked by Wall St. Rank hold ACHV as of Q3 2022.

Oppenheimer & Co reported no remaining Achieve Life Sciences position as of Q3 2022 after selling out during the quarter.
Oppenheimer & Co sold 21,300 Achieve Life Sciences shares in Q3 2022, an estimated $104K.
Oppenheimer & Co first reported a position in Achieve Life Sciences in Q2 2015 and held it in 6 quarters.
Oppenheimer & Co's Achieve Life Sciences position peaked at $213K in Q3 2021.
28 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q3 2022.

Based on Oppenheimer & Co's 13F filing for Q3 2022, filed 14 Nov 2022.